Number and cure rate of neuroblastoma cases detected by the mass screening program in Japan: future aspects.
Number and cure rate of neuroblastoma cases detected by the mass screening program in Japan: future aspects.
复制标题
日本大规模筛查计划发现的神经母细胞瘤病例数量和治愈率：未来方面。
DOI：
10.1002/mpo.2950150104
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
Y. Horii
中科院分区：
文献类型：
--
作者：
Tadashi Sawada;Tohru Sugimoto;Terufusa Tanaka;H. Kawakatsu;Takashi Ishii;Takafumi Matsumura;Y. Horii
神经母细胞瘤是一种常见的幼儿恶性肿瘤，在进展性病例中预后非常差。此前，日本每年的神经母细胞瘤发病率估计为8.2例/百万15岁以下儿童。根据1982年日本全国人口普查，这种肿瘤每年的病例数预计为220例。(Sawada等人：Med Pediatr Oncol12：101-103,1984)。在大规模筛查计划开始之前，四分之一的神经母细胞瘤病例是在一岁之前通过临床症状和其他发现发现的。自1974年以来，日本京都实施了一项通过香草扁桃酸(VMA)定性试验对6个月大婴儿进行神经母细胞瘤大规模筛查的计划，以改善神经母细胞瘤患者的预后(Sawada等人：Am J Dis Child136：710-712,1982)。神经母细胞瘤大规模筛查研究小组(NBMSSG)成立于1981年(Sawada等人：柳叶刀II：271-272,1984)，大规模筛查计划已经发展到包括八个选定的地区。该小组在247,500名6个月大的婴儿中发现了15例神经母细胞瘤，直到1983年底，每16,500名婴儿中有1例患有神经母细胞瘤，到1984年底，在434,970名婴儿中发现了23例，每18,900名婴儿中有1例。所有病例均无症状。由于该项目检测的婴儿神经母细胞瘤发病率预计为52.9-60.6例/百万6个月大的婴儿，预计日本每年将通过大规模筛查发现80-91例神经母细胞瘤病例。大规模筛查发现并随访20个月以上的25例，治愈率为92%(Sawada：Lancet I：377,1986)。在日本，每年应该可以在1岁以下的婴儿中发现135-146例[症状性55=220×1/4]+[大规模筛查发现80-91例]--(占神经母细胞瘤病例总数的61.4-66.4%)，日本所有神经母细胞瘤病例的治愈率有望达到60%或更高。
The annual incidence of neuroblastoma in Japan, a common malignancy of young children which has a very poor prognosis in progressive cases, was previously estimated to be 8.2 cases/million children under 15 years of age. Based on the Japanese National Census of the Population for 1982, the annual number of cases of this tumor is predicted to be 220. (Sawada et al: Med Pediatr Oncol 12:101-103, 1984). Before the mass screening program was started, one-fourth of all neuroblastoma cases were detected before the age of one by clinical symptoms and other findings. Since 1974, a neuroblastoma mass screening program for 6-month-old infants by means of a qualitative Vanilmandelic Acid (VMA) test has been in effect in Kyoto, Japan, for the prognostic improvement of neuroblastoma patients (Sawada et al: Am J Dis Child 136:710-712, 1982). A Neuroblastoma Mass Screening Study Group (NBMSSG) was organized in 1981 (Sawada et al: Lancet ii:271-272, 1984), and the mass screening program has grown to encompass eight selected areas. This group discovered 15 cases of neuroblastoma among 247,500 6-month-old infants, 1 of every 16,500, until the end of 1983, and 23 cases among 434,970, 1 of every 18,900, until the end of 1984. All cases were asymptomatic. As the incidence of infantile neuroblastoma detected by this program is projected to be 52.9-60.6 cases/million 6-month-old infants, it could be predicted that 80-91 neuroblastoma cases will be discovered annually in Japan by mass screening. The cure rate of 25 cases discovered by the mass screening and followed up over 20 months was 92% (Sawada: Lancet i:377,1986). In Japan, it should be possible to detect 135-146 cases--[symptomatic 55 = 220 X 1/4] + [80-91 cases detected by mass screening]--(61.4-66.4% of the total neuroblastoma cases) in infants under 1 year of age annually, and the cure rate of all neuroblastoma cases in Japan is expected to reach 60% or more.